CBIO logo

Crescent Biopharma, Inc. Stock Price

NasdaqCM:CBIO Community·US$244.4m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

CBIO Share Price Performance

US$12.51
-3.29 (-20.80%)
US$12.51
-3.29 (-20.80%)
Price US$12.51

CBIO Community Narratives

There are no narratives available yet.

Snowflake Analysis

Slight risk and overvalued.

4 Risks
1 Reward

Crescent Biopharma, Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$71.5m

Other Expenses

-US$71.5m

Earnings

Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
-3.66
0%
0%
-326.5%
View Full Analysis

About CBIO

Founded
n/a
Employees
6
CEO
Joshua Brumm
WebsiteView website
crescentbiopharma.com

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company is headquartered in Waltham, Massachusetts.

Recent CBIO News & Updates

Crescent Biopharma: Chasing The Summit Hype

Aug 18

Recent updates

No updates